Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06235580 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Genotype-phenotype Characterization Study on Genetic Diseases With Immune and Neurological Dysfunctions

Study acronym: IFN
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Notable Enrollment target: 600 to 1000
    • Start date: Dec 1, 2014 to Dec 28, 2015
    • Primary completion date: Jan 1, 2031 to Dec 27, 2030
    • Study completion date: Jan 1, 2031 to Dec 27, 2035
    v3
  2. Minor Re-verified, no change to tracked fieldsv2
  3. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Over the past twenty years, Prof. Yanick Crow and his team have developed internationally recognized expertise in genetic pathologies affecting the immune and neurological systems. The pathologies studied have a particularly severe impact on patients' quality of life, with a high mortality rate and a significant risk of occurrence in affected families. These pathologies are rare, and very often under-diagnosed. To date, there is virtually no effective curative treatment. Prof. Crow's team operates at the frontier between clinical and research work, and from experience, the team knows that patients and families affected by these serious pathologies are often highly motivated to help research into the pathology that affects them. Initially, Prof. Crow's research focused primarily on the study of the genetic disease Aicardi-Goutières Syndrome (AGS). However, there is an undeniable clinical and pathological overlap between AGS and other forms of disease such as autoimmune systemic lupus erythematosus and many other genetic pathologies - e.g. familial lupus engelure, spondyloenchondromatosis and COPA syndrome. This is why research is being extended to all genetic diseases with immune and neurological dysfunctions.
Trial Details
NCT Number NCT06235580
Lead Sponsor Imagine Institute
Conditions
(from sponsor)
Genetic Diseases, Immune Dysfunction, Neurological Disease, Autoimmune Diseases
Related terms Autoimmune Diseases, Genetic Diseases, Inborn, Immune System Diseases, Nervous System Diseases
Enrollment 1,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov